Healthcare hires of note
Here's a selection of recent executive hires across healthcare and life sciences.
Natera fires more shots in ongoing patent battle with CareDx
In the latest salvo in the ongoing legal skirmish between the two companies, Natera accused CareDx of infringing two patents covering Natera’s DNA testing technology.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Jury orders Natera to pay $44.9M in damages to CareDx for false advertising
A jury ruled that Natera owes $44.9 million in damages to CareDx on grounds that Natera intentionally mislead the transplant community regarding its Prospera Kidney Transplant Technology by likening it to CareDx's AlloSure test; the jury also ruled that CareDx engaged in two accounts of false advertising.
The second coming of consumer genomics with 3 predictions for 2018
Several fundamentals have changed to accelerate growth in the genomics space, spurring our second look into the sector.
Five things you need to know about prenatal testmaker Natera’s $175M IPO
Natera's lead product, its Panorama test, screens for fetal abnormalities, including Down syndrome, Edwards syndrome and Turner syndrome, as well as severe organ abnormalities and fetal viability.
Prenatal diagnostics maker Natera raises $55M, pivoting into precision medicine
Natera, a diagnostics company most known for its prenatal testing segment, just raised $55.5 million to expand its salesforce and marketing reach, and invest in R&D that pivots toward the field of precision medicine. The dollars will go toward expanding its global sales and marketing force, as well as expanding its R&D for existing tests and […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
California startup Natera aims to redefine prenatal testing by analyzing DNA fragments
For years, pregnant women have had a choice of undergoing traditional blood tests or more invasive and potentially dangerous procedures to rule out the chance of any chromosomal abnormalities such as Down Syndrome that may afflict their unborn child. The problem is that while the prenatal blood tests are safe and unlike the more invasive […]